Author

L. Lidemalm

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

B. Porebski· 2 shared D. Huhn· 2 shared M. Haggblad· 2 shared O. Fernandez-Capetillo· 2 shared A. Corman· 1 shared C. Hansel· 1 shared E. Sezgin· 1 shared G. Bhabha· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

B. Porebski

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Discovery of a novel inhibitor of macropinocytosis with antiviral activity

B. Porebski, W. Christ, A. Corman, M. Haraldsson, M. Barz, L. Lidemalm, M. Haggblad, J. Illmain, S. Wright, M. Murga, J. Schlegel, E. Sezgin, G. Bhabha, V. M. Lauschke, M. Lafarga, , O. Fernandez-Capetillo

This study identifies virapinib, a novel inhibitor of macropinocytosis that blocks viral entry by SARS-CoV-2, Monkeypox virus, and TBEV without host cell toxicity.

bioRxiv · Oct 25, 2023Pharmacology & Toxicology

Estrogen deprivation triggers an immunosuppressive phenotype in breast cancer cells

D. Huhn, P. Marti-Rodrigo, S. Mouron, C. Hansel, K. Tschapalda, B. Porebski, M. Haggblad, L. Lidemalm, M. A. Quintela-Fandino, J. Carreras-Puigvert, O. Fernandez-Capetillo

This study shows that estrogen deprivation in ER-positive breast cancer cells increases PD-L1 expression and triggers an immunosuppressive program, leading to resistance against T-cell killing.

bioRxiv · Aug 28, 2019 · PreprintCancer Biology